Elephas is developing a technology suite to assess how human live tumor fragments (hLTF)™ respond to cancer therapies, aiming to accelerate drug development and empower clinical decision-making.

Maneesh Arora

Jonathan Oliner

Elephas

Elephas is developing an ex-vivo technology suite to assess how live tumor fragments (LTFs) respond to immunotherapies. We seek to remove the trial-and-error approach to cancer care by harnessing the latest advances in cancer biology, advanced imaging, and artificial intelligence to accelerate drug development and empower clinical decision-making. Our unique approach maintains the native 3-dimensional cellular architecture and micro-environment of the tumor, enabling rapid real-time characterization of live tumor sample response to immunotherapies.

Sands Capital Ventures

WARF Ventures

Northpond Ventures

ARCH Venture Partners

Tao Capital Partners

Moore Strategic Ventures

There's only one week until #SITC2023! Elephas is looking forward to being in San Diego, CA from November 1-5, 2023 to discuss the latest innovations in cancer immunotherapy. https://lnkd.in/gv87X5eQ

Make sure you stop by our booth (#905) to learn more about our biopharma services offerings and how we can work together to change the view of cancer. You can schedule time to speak with Greg Ochs, our VP of Business Development, at the event here: https://lnkd.in/dauHy8DV

We also have some exciting data we're presenting at #SITC2023 that we can't wait to share with you. Stay tuned for more info!

#ChangingtheViewofCancer #PatientCare #Oncology #Immunotherapy #Cancer #Innovation #CancerResearch #ImmunoOncology #CancerImmunotherapy Society for Immunotherapy of Cancer (SITC)

Missed any of our recent posters – such as the one from AACR on label free imaging for rapid assessment of tumor viability in live tumor fragments? Head to our website to check them out now! https://lnkd.in/edtRTzkg

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch #AACR

We're excited to announce that Elephas is a 2023 Wisconsin Innovation Awards winner for Biotechnology! It was an honor to be included alongside such an amazing group of innovative companies in the state. See the announcement and full list of winners here: https://lnkd.in/gp6X6WEd 

Visit our website to learn more about our work and mission here: https://elephas.com/

At Elephas, we are committed to helping pharmaceutical and biotechnology researchers accelerate immunotherapy drug development with a novel approach for assessing response to investigational agents. Powered by Cybrid™, our technology suite is based on human live tumor fragments with the native tumor architecture and immune cells intact.

Visit our website to learn more: https://lnkd.in/eHD5iBCM

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

Elephas is comprised of a group of highly talented people, all committed to developing a transformative diagnostic solution and bringing hope to cancer patients worldwide. Head over to our website to learn more about our mission and how we can all work together to change the view of cancer. https://elephas.com/

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

Did you know that live tumor fragments are taken directly from a patient, which maintains the tumor architecture and tumor microenvironment? Cybrid™, our live tumor diagnostic platform, brings a new dimension of capabilities and insights for biopharmaceutical researchers to understand mechanisms of action and response to cancer immunotherapies.

Learn more here: https://elephas.com/cybrid

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

If you're wondering who we are, what we do, and the role we play in cancer research and drug development, visit our website to see the answers to some of your top asked questions. https://elephas.com/cybrid 

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

We know that bringing a new drug to market can be a lengthy process, but it's important that we try to get the right treatments to the right patients. To do this, we need to be able to prove that a treatment is effective for certain types of cancers, and know when it's not. With our research-use Cybrid™ platform, within two weeks* we can measure the impact of a compound on a tumor and its immune cells to help you gain insights and understand the impact on potential patients. 

Visit our website to learn more: https://lnkd.in/eHD5iBCM 

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

We understand the importance of clinical trials when it comes to cancer care. Our clinical trials will provide an opportunity to demonstrate the correlation between ex vivo platform and clinical response to immunotherapy. Visit our website to learn more. https://lnkd.in/eFRgqyep 

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

At Elephas, we are developing a technology suite to assess how human live tumor fragments respond to various cancer therapies in an effort to enable accurate prediction of clinical treatment outcomes and accelerate drug development in immuno-oncology.

If you're interested in learning more, visit our website: https://elephas.com/cybrid 

#ChangingtheViewofCancer #Immunotherapy #Cancer #Innovation #CancerResearch

Metric
Company Name	Elephas
Symbol
MSH ID	COM:ELEPHAS
Market	PRIVATE
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	135
Website	elephas.com
LinkedIn	elephasbiosciences
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ELEPHAS

Elephas

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue